Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is the only somatostatin analogue available to treat diarrhea and flushing associated with carcinoid syndrome.1,2
This section will highlight some of the benefits of Sandostatin® LAR Depot, including:
- Control that is unparalleled with Sandostatin®
- Trust in the therapy with 20 years of clinical experience
Unparalleled control with Sandostatin®
Sandostatin® is a somatostatin analogue, which is a type of medicine that works directly at the site of the carcinoid tumors to help decrease the production of hormones that lead to diarrhea and flushing associated with carcinoid syndrome. It is the only approved medical therapy for the control of these 2 symptoms associated with carcinoid syndrome.1,2
Two formulations, one therapy3,4:
With Sandostatin® LAR Depot, you get the benefit of 2 formulations that can help you maintain control over the diarrhea and flushing you might be experiencing.
While both of these treatments contain the same drug—octreotide acetate—they are each administered differently.
- Prior to beginning treatment with Sandostatin® LAR Depot, some patients may be started on 2 weeks of Sandostatin® (octreotide acetate) Injection
- While a patient is on Sandostatin® LAR Depot, periodic symptom flare-ups can be treated with Sandostatin® Injection
According to the National Comprehensive Cancer Network, patients who are experiencing diarrhea and flushing associated with carcinoid syndrome should be started on Sandostatin® LAR Depot for symptom control.
Trust in 20 years of clinical experience
Sandostatin® offers you:
- 20 years of unparalleled evidence, established through*6,7
- Over 6000 published articles6,8
- Over 600 clinical trials†6,8
*Combined use of immediate release Sandostatin® Injection and Sandostatin® LAR Depot for all approved indications.
†Includes both ongoing and completed trials for all approved indications.
Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is indicated for long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and for the long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors in patients in whom initial treatment with immediate release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated.
Important Safety Information3
As with immediate release Sandostatin® Injection, the most frequently reported drug-related adverse events were biliary disorders (62%), gastrointestinal disorders (14% to 38%), and injection-site pain (20% to 50%). Hypoglycemia (4%), hyperglycemia (27%), sinus bradycardia (19%), conduction abnormalities (9%), and arrhythmias (3%) have been reported.
The controlled clinical trials that support the marketing clearance for Sandostatin® LAR Depot did not include determination of effect on tumor size or rate of growth. Sandostatin® LAR Depot is not indicated for tumor shrinkage. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
